摘要
目的:观察艾塞那肽联合二甲双胍治疗2型糖尿病的有效性及安全性。方法:将肥胖型2型糖尿病80例随机分为实验组和对照组。实验组给予艾塞那肽联合二甲双胍治疗,对照组给予二甲双胍治疗。观察2组患者治疗第0月、第1月、第2月、第3月时FBG、2hBG、HbA1c、BMI、TC、TG和LDL水平。检测3个月治疗结束时两组患者的C肽水平,并进行比较。结果:2组患者治疗3个月后,FBG、2hBG、HbA1c和BMI均显著下降,与治疗前相比差异具有显著性(P<0.05)。同时实验组较对照组显著下降(P<0.05)。对照组的TC、TG和LDL较治疗前降低,但差异无显著性(P>0.05)。而实验组较治疗前显著降低(P<0.05),同时较对照组显著下降(P<0.05)。治疗3个月后,实验组的C肽水平显著高于对照组(P<0.05)。结论:肥胖型2型糖尿病应用艾塞那肽联合二甲双胍可获得良好的血糖、体质量和血脂控制,同时可改善胰岛功能,不增加低血糖发生,安全有效。
OBJECTIVE To explore the effect and safety of combination of exenatide and metformin in treatment of fatty type 2 diabetic patients. METHODS Totally 80 fatty type 2 diabetic patients were randomly divided into experimental group and control group. Experimental group received exenatide combined with metformin treatment for 3 months,and control group received metformin therapy. Fasting blood glucose （FBG）, 2 h postprandial blood glucose （2hPG）, glyeosylated hemoglobin （HbA1c）, body mass index （BMI）, total cholesterol （TC）, total triglyceride （TG） and low density lipoprotein （LDL） of two groups were measured on month 0, 1st, 2na and 3ra respectively. C peptide levels were also detected on month 3ra. RESULTS FBG, 2hPG, HbAIc and BMI of two groups decreased significantly on month 3rd （P〈0. （15）. Compared with control group, FBG, 2hPG, HbAlc and BMI of experimental group were decreased significantly （P〈0. 05）. After 3 months, the TC,TG and LDL of experimental group were much lower than those of control group （P〈0. 05）, and C peptide levels of experimental group were much higher than those of control group （P〈0. 05）. CONCLUSION Combination of exenatide and metformin can significantly decrease blood glucose, reduce weight gain and serum lipid, improve insulin function, which is a safe and effective therapy strategy for fatty type 2 diabetic patients.
出处
《中国医院药学杂志》
CAS
CSCD
北大核心
2013年第17期1418-1420,共3页
Chinese Journal of Hospital Pharmacy
作者简介
牛力，男，博士，主治医师，研究方向：糖尿病的防治，电话：13545058443，E-mail：type2dm@126．com
[通讯作者]洪畋，女，主治医师，电话：15972131426，E-mail：hongtian131426@126．com
